Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Radiotherapy as primary treatment modality.

M Sia1, T Rosewall, T P Warde

  • 1Department of Radiation Oncology, University of Toronto, and Radiation Medicine Program, Princess Margaret Hospital, Toronto, Ont. , Canada.

Frontiers of Radiation Therapy and Oncology
|June 12, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Geometric and dosimetric impact of inter-professional contour variability in the upper abdomen for MR-linac.

Journal of medical imaging and radiation sciences·2025
Same author

Eliminating tattoos for short course palliative radiation therapy: Set-up error, satisfaction and cost.

Journal of medical imaging and radiation sciences·2022
Same author

Corrigendum to 'Can Conformity-Based Volumetric Modulated Arc Therapy Improve Dosimetry and Speed of Delivery in Radiation Therapy to Lumbosacral Spine Compared with Conventional Techniques?' [Journal of Medical Imaging and Radiation Sciences Volume 51 Issue 3 (2020) 404-410/814].

Journal of medical imaging and radiation sciences·2020
Same author

Pathologically Node-Positive Prostate Carcinoma - Prevalence, Pattern of Care and Outcome From a Population-Based Study.

Clinical oncology (Royal College of Radiologists (Great Britain))·2018
Same author

Sci-Sat AM: Brachy - 09: Permanent seed re-implantation using image guidance for composite dose planning.

Medical physics·2017
Same author

Intra-prostatic fiducial markers and concurrent androgen deprivation.

Clinical oncology (Royal College of Radiologists (Great Britain))·2005
Same journal

Proton therapy in the clinic.

Frontiers of radiation therapy and oncology·2011
Same journal

Proton therapy: clinical gains through current and future treatment programs.

Frontiers of radiation therapy and oncology·2011
Same journal

Stereotactic body radiotherapy for prostate cancer: current results of a phase II trial.

Frontiers of radiation therapy and oncology·2011
Same journal

Stereotactic body radiation therapy for gastrointestinal malignancies.

Frontiers of radiation therapy and oncology·2011
Same journal

Stereotactic body radiation therapy for thoracic cancers: recommendations for patient selection, setup and therapy.

Frontiers of radiation therapy and oncology·2011
Same journal

Stereotactic body radiation therapy: normal tissue and tumor control effects with large dose per fraction.

Frontiers of radiation therapy and oncology·2011
See all related articles

Managing prostate cancer requires accurate risk assessment. Radiotherapy is effective for low- and intermediate-risk disease, but optimal use of hormonal therapy and hypofractionation requires further study.

Area of Science:

  • Oncology
  • Radiation Oncology
  • Urologic Oncology

Background:

  • Prostate cancer management relies on risk stratification using PSA, clinical stage, and Gleason score.
  • Radiotherapy is a standard treatment for localized prostate cancer, with outcomes comparable to surgery.
  • Adjuvant hormonal therapy and hypofractionated radiotherapy are areas of ongoing investigation for improving outcomes.

Purpose of the Study:

  • To review the current role and future directions of radiotherapy in prostate cancer management.
  • To evaluate the use of adjuvant hormonal therapy in different risk groups.
  • To explore the potential benefits and optimal regimens of hypofractionated radiotherapy.

Main Methods:

  • Review of established radiotherapy protocols for prostate cancer.

Related Experiment Videos

  • Analysis of existing data on adjuvant hormonal therapy efficacy in various risk categories.
  • Discussion of emerging techniques like hypofractionated radiotherapy and dose escalation.

    • Main Results:

    • Radiotherapy is effective for low- and intermediate-risk prostate cancer.
    • The role of adjuvant hormonal therapy in low-risk disease is unclear; its benefit in intermediate-risk disease needs further evaluation with dose-escalated radiation.
    • Hypofractionated radiotherapy offers potential for improved therapeutic index and reduced treatment time, but optimal regimens are undetermined.

    Conclusions:

    • Risk stratification is crucial for appropriate prostate cancer treatment selection.
    • Further research is needed to define the optimal use of hormonal therapy and hypofractionation in radiotherapy for prostate cancer.
    • Standard treatment for high-risk disease involves radiation with hormones, with ongoing questions about hormone duration, dose escalation, and chemotherapy benefits.